Featured Studies
Explore the clinical evidence behind CareDx technologies, including landmark trials and registries advancing modern transplant care.
KOAR is a large real-world registry of kidney transplant outcomes, tracking over 1,700 patients across 56 centers. This pivotal study demonstrated that AlloSure donor-derived cell-free DNA testing enables earlier detection of rejection and was shown to improve biopsy yield.
Bromberg, Kothari. dd-cfDNA Significantly Improves Rejection Yield in Kidney Transplant Biopsies. American Journal of Transplantation. 2025
1,743 patients across 56 transplant centers
One of the largest multicenter prospective studies on kidney transplantation
Elevated AlloSure® detected rejection risk up to 4 months before biopsy
4x higher likelihood of detecting rejection on for-cause biopsies in patients with elevated AlloSure®
6x higher likelihood of detecting rejection on surveillance biopsies in patients with elevated AlloSure®
SHORE, a landmark, prospective, observational, multicenter registry in heart transplant. The pivotal study demonstrated the clinical utility and prognostic value of HeartCare.
Khush, Teuteberg. Surveillance with dual noninvasive testing for acute cellular rejection after heart transplantation: Outcomes from the Surveillance HeartCare Outcomes Registry. Journal of Heart and Lung Transplantation. 2024
Teuteberg, Uriel. Multimodal Molecular Testing Provides Prognostic Value for Heart Transplant Recipients . Journal of Heart and Lung Transplantation. 2025
2,732 transplant patients across 67 transplants centers in United States since 2018
97.3% of patients monitored with HeartCare had normal graft function at 2 yrs
Patients monitored with HeartCare had a 94.9% survival rate at 2 years
Patients with AlloMap(+) AlloSure(+) are 6x more likely to have biopsy confirmed ACR compared to -/- result.
Patients with AlloMap(+) AlloSure(+) were ~2X more likely to experience poor outcomes, even in absence of histological rejection.
This peer-reviewed study in Nature Medicine validated AlloSure® as a powerful, noninvasive tool for detection of kidney transplant rejection.
Aubert, Loupy. Cell-free DNA for the detection of kidney allograft rejection. Nature Medicine. 2024
AlloSure improved rejection detection across clinical scenarios and timepoints post-transplant
AlloSure is highly associated with the severity of all types of rejection
AlloSure detects molecular injury before other clinical signs of rejection are apparent
Full List of Publications & Peer-Reviewed Evidence
